DELIVER FRESH INSIGHTS MONTHLY, WITH NYCU

1 May 2026

Doxorubicin is a chemotherapy drug commonly used to treat cancers such as breast cancer, lymphoma, and leukemia, and the issue of cardiotoxicity it causes has plagued the medical field for over half a century. Statistics show that approximately 5-9% of patients develop significant heart failure or cardiomyopathy following treatment, and the risk of developing chronic heart failure within 10 years ranges from 4-10%.

 

Recently, a research team from National Yang Ming Chiao Tung University (NYCU) confirmed that Doxorubicin’s suppression of the longevity gene CISD2 is one of the key mechanisms underlying its cardiotoxicity, while “hesperidin,” abundant in citrus peel, can be converted into “hesperetin,” which powerfully activates CISD2 and protects cardiac function without compromising Doxorubicin’s anticancer efficacy. In August 2025, the findings...

 


MORE +
MORE +
MORE +
 
 
 
MORE
Research Highlights
NYCU Study Identifies Key Gene Linking Gut Microbiota, Circadian Rhythm, and Metabolic Disease
Campus Life
NYCU Marks 5th Anniversary with Opening Ceremony at Bo-Ai Campus, Showcasing Renewal and Future Vision
Honorary Doctorate NYCU Awards Honorary Doctorate to Renowned Photonics Scientist Jia-Ming Liu
Honor NYCU Professors Honored with Prestigious Awards for Breakthroughs in Brain and Liver Research